According to Zacks, “Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company’s lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif. “
Separately, Maxim Group began coverage on shares of Unicycive Therapeutics in a research note on Wednesday, March 16th. They issued a “buy” rating and a $3.00 target price on the stock.
Hedge funds have recently made changes to their positions in the company. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $700,000. BlackRock Inc. bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $33,000. Geode Capital Management LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $73,000. Finally, Two Sigma Investments LP bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $72,000. Hedge funds and other institutional investors own 13.46% of the company’s stock.
About Unicycive Therapeutics (Get Rating)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
- Get a free copy of the StockNews.com research report on Unicycive Therapeutics (UNCY)
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.